eliprodil
Small moleculeexperimental
Eliprodil is an NMDA antagonist drug candidate which selectively inhibits the NR2B (GLUN2B) subtype NMDA receptor at submicromolar concentrations. Eliprodil failed a Phase III clinical trial for the treatment of acute ischemic stroke in 1996, sponsored by Synthélabo Recherche. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 1999 (NCT00001929)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Cytochrome cINHIBITOR
CYCS inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
OC(CN1CCC(Cc2ccc(F)cc2)CC1)c1ccc(Cl)cc1- Mol. weight
- 347.86 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEliprodil ↗
- ChEMBLCHEMBL28564 ↗
Also known as
- 1-piperidineethanol, alpha-(4-chlorophenyl)-4-(4-fluorophenyl)-, (+-)-
- (4-chlorophenyl)-4-((4-fluorophenyl)methyl)-1-piperidineethanol
- eliprodil
- eliprodil
- eliprodil
- eliprodil
- eliprodil
- sl 82-0715
- sl 82.0715
- sl-820715
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00001929 | Phase 2 | Mar 1, 1999 | National Institute of Neurological Disorders and Stroke (NINDS) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 1 | 1 | 1999 |
1 organizations
Page 1 / 1